Kairos Pharma, Ltd. (KAPA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, Ltd. on June 4, 2026. The filing serves to disseminate a press release (Exhibit 99.1) summarizing the Company's achievements for the first half of 2026 and outlining key milestones expected by the end of 2026. The Company is an emerging growth company incorporated in Delaware.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a conduit for a press release rather than a detailed financial statement. Investors must refer to the attached Exhibit 99.1 for specific financial data.
Material Changes
The filing does not detail specific material changes in financial position or operations within the text of the 8-K itself. It references a summary of achievements for the first half of 2026, but the specific nature of these changes is contained in the furnished press release.
Guidance, Outlook, and Risks
Management has provided an outlook regarding key milestones the Company expects to reach by the end of 2026, as detailed in the press release. The filing includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific financial achievements and operational milestones for the first half of 2026 by reviewing Exhibit 99.1 (Press Release dated June 4, 2026).
- Confirm the details of the expected end-of-2026 milestones referenced in the press release.
- Note that the information in this 8-K is furnished and not "filed" for liability purposes under Section 18 of the Exchange Act.
- Check the Company's status as an emerging growth company and any associated reporting implications.